Usted buscó: farmakodinamičkim (Croata - Inglés)

ova se preporuka temelji na farmakodinamičkim i farmakokinetičkim podacima.
this recommendation is based on pharmacodynamic and pharmacokinetic data.

nema dostupnih podataka o farmakodinamičkim svojstvima u djece mlađe od 18 godina.
there are no data available on pharmacodynamic properties in children below 18 years of age.

nisu uočene razlike u farmakodinamičkim svojstvima između odraslih osoba i djece u ispitivanjima.
no differences were seen in the pharmacodynamic properties between adult and paediatric study patients.

nisu uočene razlike u farmakodinamičkim svojstvima između studija za odrasle osobe i za djecu.
no differences were seen in the pharmacodynamic properties between adult and paediatric study patients.

nisu uočene razlike u farmakodinamičkim svojstvima između studija za odrasle osobe i za starije bolesnike.
no differences were seen in the pharmacodynamic properties between adult and elderly study patients.

prema postojećim farmakodinamičkim podacima, indinavir se mora primjenjivati u kombinaciji s drugim antiretrovirusnim lijekovima.
on the basis of current pharmacodynamic data, indinavir must be used in combination with other antiretroviral agents.

međutim, to bi moglo biti povezano s visokom dozom ruksolitiniba koja rezultira farmakodinamičkim učincima blizu emax.
however, this could be related to the high ruxolitinib dose resulting in pharmacodynamic effects near emax.

takav je porast broja leukocita prolazan, tipično se uočava od 24 do 48 sati nakon primjene lijeka i u skladu je s farmakodinamičkim učincima ovog lijeka.
such elevation in white blood cells is transient, typically seen 24 to 48 hours after administration and is consistent with the pharmacodynamic effects of this medicine.

iako posebne informacije o farmakodinamičkim interakcijama u središnjem živčanom sustavu nisu dostupne o njima treba razmišljati kada se istovremeno propisuju lijekovi koji imaju sedativni učinak na središnji živčani sustav.
although no specific information on pharmacodynamic interactions in the central nervous system is available, this should be borne in mind when co-prescribing medicinal products with central nervous system depressant action.

očekivane nuspojave su one povezane s farmakodinamičkim profilom agonista dopamina, uključujući mučninu, povraćanje, hiperkineziju, halucinacije, agitaciju i hipotenziju.
the expected adverse events would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.

emtricitabin i tenofovir su u farmakodinamičkim ispitivanjima pojedinačno i u kombinaciji pokazali aktivnost protiv hbv-a (vidjeti dio 5.1).
emtricitabine and tenofovir individually and in combination have shown activity against hbv in pharmacodynamic studies (see section 5.1).

kod bolesnika s dvt/pe, preporučena primjena pradaxe 220 mg uzeta u obliku jedne kapsule od 110 mg dvaput dnevno zasniva se na farmakokinetičkim i farmakodinamičkim analizama te nije ispitivana u ovom kliničkom okruženju.
for dvt/pe the recommendation for the use of pradaxa 220 mg taken as one 110 mg capsule twice daily is based on pharmacokinetic and pharmacodynamic analyses and has not been studied in this clinical setting.

najvjerojatnije nuspojave bi bile one koje su povezane s farmakodinamičkim svojstvima agonista dopamina, uključujući mučninu, povraćanje, hipotenziju, nevoljne pokrete, halucinacije, konfuziju, konvulzije i ostale znakove središnje dopaminergičke stimulacije.
the most likely adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hypotension, involuntary movements, hallucinations, confusion, convulsions and other signs of central dopaminergic stimulation.